BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

A recent Turkish study published in Ophthalmic Epidemiology suggests the Pfizer-BioNTech COVID-19 vaccine may cause subtle ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come ...

Scientists in Turkey found that the Pfizer COVID-19 vaccine impacted some people's corneas, according to a study.

A Turkish study finds Pfizer’s COVID-19 vaccine may cause temporary changes in corneal thickness and cell count, raising concerns for those with existing eye issues or transplants.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Turkish scientists say that Pfizer's COVID-19 vaccine can increase the risk of eye damage, causing vision loss. A new study ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...